Aliases:This biomarker is also known as:
TMPRSS2:ERG gene fusions are a common genetic event in prostate cancer. These fusions are specific for prostate cancer and have also been observed in precursor lesions. Since TMPRSS2:ERG fusions are not seen in every prostate cancer, their utility is in assays combined with other biomarkers, such as PCA3.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
TMPRSS2:ERG urine assay for prostate cancer detection is in studies in CLIA lab and is undergoing phase 3 validation.
The combined measurement of PCA3 and TMPRSS2:ERG in urine outperformed serum PSA for prostate cancer diagnosis. The detection of TMPRSS2:ERG fusion in urine has greater than 90% specificity and 94% positive predictive value for prostate cancer detection. Increased TMPRSS2:ERG transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.
- Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
- Correlation of Urine TMPRSS2:ERG and PCA3 to ERG+ and Total Prostate Cancer Burden.
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
- Beyond PSA: the next generation of prostate cancer biomarkers.
- Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.